Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

(MedPage Today) -- CHICAGO -- Teclistamab (Tecvayli) monotherapy significantly improved survival compared with standard therapies in patients with multiple myeloma who had received up to three previous lines of therapy, the phase III MajesTEC...
Source
MedPage Today
Opens original article in a new tab



